ProQR Therapeutics announces $8.1M in new funding from RSRT

ProQR Therapeutics (PRQR) announced an expansion of its collaboration with the Rett Syndrome Research Trust, RSRT. Building on the initial $1 million research grant announced in January 2024, the expanded partnership includes an additional $8.1 million in funding from the RSRT, for a total of $9.1 million. The funding will support the advancement of AX-2402 into clinical trials. The additional $8.1 million in funding will enable ProQR to accelerate work on RNA editing approaches tailored to the genetic mutations that cause Rett Syndrome. This next phase of the collaboration will focus on optimizing therapeutic candidates targeting the transcription factor Methyl CpG binding protein 2 and advancing them toward clinical development.